Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Biopharm Knowledge Publishing | Virtual Pharma - the radical route to success

Virtual Pharma - the radical route to success

Mega mergers and the blockbuster model have not delivered the benefits that were claimed for them - growth in the pharmaceutical market has slowed to no more than five per cent and the world's biggest companies are growing slowly, if at all. Against that background pharmaceutical companies, large and small, are looking for new ways to do business - ways that will bring success in a difficult market. For ways to discover and deliver new drugs, to manufacture them more cost-effectively and to sell and market them more successfully.

There is a solution, a radical new approach, the virtual company - the company that retains key skills but outsources everything else, including:

* discovery research

* drug development

* manufacturing

* sales and marketing

This detailed and comprehensive report will help you to:

* understand the virtual pharma business model

* see what can be outsourced

* focus on the advantages

* avoid the pitfalls

* manage the outsourcing process

* understand what to keep in house

The report, was written by Dr John MacDonald a company analyst for IMS Health and a pharma industry analyst for PricewaterhouseCoopers.

This report is essential reading for anyone in the biotech, pharmaceutical and clinical outsourcing industries from corporate management through development and research to marketing and sales. It gives an authoritative, detailed and clear explanation of the issues surrounding the virtual pharma business model and its implications for the market and for the biotech and pharmaceutical industries.

September 2008 PDF Pages: 92
Table of Contents

Price

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions